Introduction
Over the two last decades, the striking improvement in prognosis of testicular germ-cell tumors (GCTs) was mainly attributable to the development of more effective chemotherapies [1] [2] [3] [4] . For patients who do not achieve lasting complete response (CR) to chemotherapy (CT), the introduction of ifosfamide (IFM) combined with vinblastine (VLB) plus cisplatin in the VeIP regimen may offer a 25 -40% CR rate [5, 6] . The outcome of patients with primary extra-gonadal GCTs (EGCTs) varies [4] . A review of 635 cases of EGCTs allowed Hartmann et al. to produce some prognostic risk groupings: 'excellent prognosis', all seminomatous EGCTs (89% 5-year survival rate), 'intermediate low', 'intermediate high' and 'poor', all non-seminomatous EGCTs with a 69%, 55% and 17% 5-year survival rate, respectively [7] . For patients who relapse or exhibit inadequate response after a conventional-dose salvage regimen, high-dose chemotherapy (HD-CT) using a carboplatin-based regimen supported by peripheral blood stem cell transplantation (PBSCT) overcomes the resistance to conventional CT [8 -15] . HD-CT may also increase response rate and survival when given as first-salvage treatment in cisplatin-sensitive patients [16] [17] [18] . However, despite the use of HD-CT, long-term remissions after salvage treatment can only be expected in 10 -40% of patients, depending on risk factors, notably the location of the primary tumor and at first, the degree of sensitivity to cisplatin [19, 20] . To improve the results of HD-CT, old and new drugs are to be revisited. Epirubicin provides a biological response rate of 50% in refractory diseases [21, 22] . Paclitaxel has been shown to be effective in around 20% of patients with resistant disease, both as a single agent or in combination [23] [24] [25] . Moreover, the combination of epirubicin and paclitaxel supported by granulocyte colony-stimulating factors (G-CSF) is capable of stem cell mobilization and their use as first-line therapy before HD-CT seems logical [26, 27] . Among the older drugs, thiotepa and cyclophosphamide (CPM), both suitable for HD-CT and efficient in GCTs, have been studied by Rodenhuis et al. [28] . In view of these data, we decided to develop a high-dose protocol combining two courses of epirubicin and paclitaxel as front-line therapy, followed by three HD-CT cycles (thiotepa and CPM for the first, etoposide, ifosfamide and carboplatin for the second and the third courses), in the treatment of relapsed poor prognosis GCTs. We present the final results herein of this so-called 'TAXIF' regimen [29] .
Materials and methods

Patient selection and characteristics
The treatment was designed for relapsed poor prognosis patients with testicular or extra-gonadal GCTs previously treated with cisplatin-containing regimens. Poor prognosis patients were defined as either refractory with increasing tumor markers less than 1 month after cisplatin administration, whether in the course of first-line CT or in that of salvage treatment, or patients who showed evidence of progression after at least two lines of cisplatin-containing CT (i.e. BEP and VeIP). Eligibility requirements included the following criteria: age >15 and <65 years, using ECOG performance status <3, histologically or biologically documented GCTs, testicular, abdominal or mediastinal tumors, measurable or evaluable disease, life expectancy >3 months, normal cardiac, liver, and renal function tests, absence of infection, HIV negative test, and signed informed consent. All patients had to have been previously treated with at least one line of a cisplatin-containing regimen and were included if they were refractory after one or two line(s) of cisplatin-based CT, or had relapsed after two lines of a cisplatin-based CT. Non-inclusion criteria were: growing teratoma syndrome, possibility of being treated with a conventional cisplatin-based CT, and previous HD-CT regimen. The study protocol was approved by the Ethics Committee of the University of Medicine in Lyon, France.
Initial evaluation
Each patient underwent clinical evaluation that included measurements of tumor marker levels, and an imaging work-up. The tumor marker levels were determined throughout the sequence of treatment (normal level <10 ng/ml for alpha-fetoprotein and <2 mIU/ml for HCG). The tumor mass was measured after the first two cycles of induction/mobilization therapy and at the end of the treatment.
Chemotherapy
Patients were scheduled to receive two courses of front-line mobilization CT followed by 3 HD-CT supported by PBSCT. The front-line treatment consisted of a combination of epirubicin (100 mg/m 2 
Evaluation of toxicity, response to therapy and survival
This phase II study was initially designed as a Gehan method [30] . The main objective of the study was the CR rate. With this aim in view, we planned to enroll 14 patients in a first phase to ensure that if no CR was observed, the study would be stopped for inefficacy (i.e. a CR rate lower than 20%). If one or more CR were observed, the protocol specified that up to 45 patients could be included in order to reduce the confidence interval (CI) of the CR rate. Secondary objectives were the overall (complete plus partial) response rate (RR), overall survival (OS) and progressionfree survival (PFS) rates, toxicity and toxic death rate. The statistical analysis was done in terms of intention-to-treat. Toxicity and response to therapy were evaluated according to the ECOG and WHO criteria [31, 32] .
The duration of response was calculated from the date of documented response to the date of progression. Whenever possible, patients in clinical partial response (PR) with normal tumor markers (PRm-) underwent surgery of residual masses at the end of the whole procedure. Sequential procedures were proposed in the case of multiple metastatic sites. If surgery was complete and the pathological examination did not show any viable tumor, patients were considered as complete responders. If surgery was complete and the pathological examination showed persistent viable tumor, they were considered as surgical CR [20] . Progression, death from treatment and withdrawal from protocol for whatever reason were considered as treatment failures.
The duration of PFS and OS was calculated from the date of inclusion to the date of progression, or death if no progression (PFS), and the date of death (OS), according to Kaplan-Meier's method [33] . The patients were stratified into good-, intermediate-, and poor-risk categories on the basis of a cumulative score calculated using a prognostic index proposed by Beyer et al. [20] . One point each was given for progressive disease before HD-CT and non-seminomatous mediastinal primary or refractory disease before HD-CT. Two points were given for HCG levels greater than 1000 mIU/ml before HD-CT or absolute refractory disease. Patients with a cumulative score greater than 2 were in the poor-prognosis group and those with a score of 0 were in the good-prognosis group.
Results
Characteristics of the patients (Table 1) This phase II study was carried out in 12 institutions during a 3.5-year period March 1998 to September 2001. Forty-five patients (median age: 28 years, range: 17.3-47.2) were included in the study. Median PS was 0 (range: 0-2). Among these 45 patients, 34 (75.6%) exhibited testicular cancer, six (13.3%) primary mediastinal tumors, three (6.7%) retroperitoneal GCT, one (2.2%) primary hepatic GCT, and one (2.2%) had an unknown primary GCT. Forty patients (89%) exhibited non-seminomatous GCT (NSGCT) and five (11%) a pure seminoma.
Seven patients (15.5%) were included while they progressed during their first line therapy, which was BEP for all of them. Thirty-two (71%) patients were included because they had relapsed after two lines of therapy (BEP and VeIP), and six (13.5%) entered the study after more than two lines of therapy. The median delay between day 1 of the first treatment and the day of inclusion was 11.1 months (range: 1.9-181.3). Administration of chemotherapy ( Table 2) Four out of the 45 patients who had received the first cycle were excluded before the second cycle of CT: one died from therapy-related toxicity, three from progressive disease. Hence, 41 patients were eligible to receive the second mobilization course. Following this second course, eight patients were excluded (six for progression, one for harvest failure, and one who died from toxicity). Thirty-three patients underwent the first HD-CT course. Four were excluded after this third cycle, three for hematologic toxicity, one for toxic death. Twenty-nine patients were eligible to receive the first ICE regimen. Seven supplementary withdrawals were due to various reasons: two for progression, two toxic deaths, two for toxicity including one hemorrhagic cystitis and one hematologic toxicity, and one refusal. Finally, 22 patients (49%) were eligible to receive the complete course of treatment. The median number of CD34+ cells harvested at the end of the mobilization sequence was 10.5 Â 10 6 CD34+/kg of BW.
Harvesting was successful in 30 patients after the first course of mobilization, six required a second series of apheresis and three patients required a third course. In 10 patients, the harvest was insufficient with two cases of sepsis and one acute respiratory distress syndrome. Harvesting failed in only one patient. 
Toxicity
The 45 patients included in the study were assessable for toxicity. Hematologic toxicity. One hundred and seventy-four cycles of chemotherapy were assessable for hematologic toxicity, with 89 for epirubicin-paclitaxel and 85 for cycles of HD-CT. One hundred and seven courses (61.5%) were complicated by grade IV neutropenia and 79 (45.4%) by grade IV thrombocytopenia. Seven cases of grade IV anemia occurred during the therapy. The median number of red blood cell unit transfusions per patient was 15 (range: 6-26) and the median number of platelet unit transfusions per patient was 13 (range: 1-24). Extra-hematologic toxicity. Two grade IV toxic effects consisting of cerebral hemorrhage occurred in two patients among the four exhibiting cerebral metastases. Twenty-one patients suffered from grade IV vomiting despite the use of 5-HT3 antagonists. Two reversible grade III liver toxic effects occurred, one related to the use of thiotepa and carboplatin. Four grade III and three grade IV episodes of fever were reported. One reversible IFM-related grade IV central neuropathy occurred. One patient suffered from CPM-related hemorrhagic cystitis. Finally, no grade III or IV renal toxicity was observed in this trial. Treatment-related deaths. Five patients died from therapyrelated complications: one after each of the two mobilization cycles, one after the first HD-CT cycle, and two after the first ICE cycle. The treatment-related death rate in this poor-prognosis population was 11%. Among the four patients with cerebral metastases, two died from cerebral hemorrhage, one after the first mobilization cycle and one during the first ICE regimen. Three patients (6.6%) died from non-hematologic toxicity: one from acute respiratory syndrome, one from a toxic shock syndrome during the first HD-CT course, and one from multi organ failure during the first ICE regimen.
Response to therapy ( Nine patients underwent surgery at the end of the chemotherapy sequence. Among the three patients who were in PR, two exhibited a pathological CR. The other six patients were progressive (n = 2) or had disease that did not classify as CR, PR or progressive disease (n = 4); salvage surgery was complete for all of them, but residual tumors were histologically active in all of them.
Survival (Figures 1-3)
Twenty-five patients (55.5%) died from disease progression. The median OS for the whole population was 11.8 months (95% CI: 8.3-13). The 3-year survival rate was 23.5% (95% CI: 15.2-42.4) with a plateau starting at 17 months. The median PFS time was 6 months (95% CI: 4.8-7.5) and the 3-year PFS rate was 23.5% (95% CI: 13.8 -38.1), with a plateau starting at 13 months. The median time to progression was 6 months (Figure 1) . According to the 'Beyer' classification, OS and PFS were better in patients graded as '0' than in patients graded as '1 -2' or more (Figures 2 and 3) . The 3-year PFS rate of patients graded as '0' was 62%, compared with 13% for patients graded as '1 -2' and 0% for patients graded as '>2'.
Discussion
Salvage HD-CT for relapsed poor prognosis GCTs has been associated with a high RR and long-term DFS, except in absolute refractory patients, i.e. patients who never respond to therapy. In our trial, with an overall RR of 37.7%, we obtained a median OS of 11.8 months for the whole population, and a 3-year survival rate of 23.5%, with a plateau starting at 17 months. This protocol of 3 HD-CT was associated with a relatively high rate of acute non-lethal toxicity. The 11% toxic death rate, not unusual for relapsed poor prognosis patients, was partly due to cerebral hemorrhage observed in 50% of the patients exhibiting cerebral metastases. These patients should be carefully managed in terms of platelets count monitoring (maintenance of a platelets count >50 Â 10 9 /l) and cerebral irradiation could be discussed beforehand. Moreover, in order to increase the tolerance to HD-CT, decrease the acute toxicity, and notably hematopoietic and renal toxicity, the toxic death rate and finally to minimize the risk of severe delayed toxicity, such as peripheral neuropathy, chronic renal toxicity, or chemotherapy-induced cancer, less heavily pre-treated patients should be targeted [34] .
The prognostic score predicts the outcome after HD-CT. Analysis of survival has shown that no long-term survivors were observed among the patients graded with a 'Beyer' score greater than 2. These results confirm that highly refractory patients and particularly patients with resistant/refractory primary mediastinal GCTs, clearly did not benefit from HD-CT. Selection of patients who could benefit from HD-CT should be respected ('Beyer' score 0-2) whereas new drugs (gemcitabine, oxaliplatin and paclitaxel) should be proposed within clinical trials for patients with a score greater than 2 [35] . Prognosis of patients graded '1-2' certainly remains poor, but these patients should however be treated within HD-CT clinical trials.
Vaena et al. [36] have published similar results in their retrospective study. In a population of 80 patients who received salvage HD-CT between 1988 and 2001 and exhibited at least one poor-prognosis characteristic (platinumrefractory or absolutely platinum-refractory GCT, primary mediastinal NSGCT, HCG > _ 1000 mIU/ml or alpha-fetoprotein > _ 1000 ng/ml before HD-CT), the authors reported a median OS of 14.7 months, a 2-year PFS of 32%, and no relapse had occurred 2 years after HD-CT [36] . The optimal salvage treatment for patients with relapsed or refractory disease remains controversial [37] . In the 1990's, a series of HD-CT for previously treated patients yielded 15 -25% lasting CR rates. These poor results have been attributed to various factors, including poor PS, refractory disease and high treatmentrelated death rates [38] . Improved results in terms of toxicity and response or survival have been observed with an earlier administration of HD-CT [14, 38 -41] . Bhatia et al. obtained a 57% relapse-free rate (RFR) at 39 months in a population of 65 patients treated in first relapse with one or two cycles of VeIP followed by two HD cycles of carboplatin -etoposide [14] . In this study, patients with EGCTs were excluded and only two patients were in progression during initial cisplatinbased treatment. Response to VeIP chemotherapy before HD-CT as well as response to HD-CT itself predicted long-term DFS. Likewise, Rodenhuis et al. obtained a RFR of 54% at 37 months in a population of 35 previously CR patients treated with conventional induction and two high-dose regimens combining carboplatin, thiotepa and CPM [41] . However, the results of the first prospective randomized study were disappointing. The EBMT-IT-94 study failed to demonstrate the superiority of a single course of HD-CT (CARBOPEC), administered after three courses of conventional CT (VeIP or VIP) versus four courses of conventional VeIP or VIP protocols for patients with advanced GCTs, who had relapsed after previous CR or achieved an incomplete remission or failed to normalize tumor markers after first-line therapy [42] . Overall CR and PRm-rates were 41 and 17% in the standard arm and 44 and 18% in the HD arm, respectively. The 1 year event-free survival (EFS) rates were 48 and 52%, respectively (P = n.s.). Finally, the 3-year OS rate was 53% in the two arms.
In our study, we have tried to optimize the concept of salvage therapy. First, in view of its efficacy in controlling the progression of the disease and its ability to mobilize PBSC, we proposed to combine epirubicin and paclitaxel [21-25, 43, 44] . Secondly, we decided to give two consecutive courses of epirubicin and paclitaxel. Indeed, several studies have investigated the use of multiple paclitaxel-based salvage therapy [43] [44] [45] [46] . Motzer et al. obtained a RFR of 41% at 30 months in a population of 37 patients treated in first relapse [43] . Several important differences should be underlined in this single center study: patients with brain metastases were ineligible, the only patient who developed brain metastases during induction therapy was excluded from the HD sequence, only 3% of the patients were pre-treated with more than two lines of CT, compared with 13.5% in our trial, and finally, no toxic deaths were observed during the whole sequence. Moreover, the surgical approach differed between the two studies. In our study, only nine out of the 22 patients who received the whole sequence of treatment underwent surgery; three were in PR, four had stable disease, and two were in progression. Only two of these achieved a pathological CR. In Motzer's study, 21 patients (57%) achieved a CR, of whom 18 required resection of residua; 14 patients were in CR to chemotherapy alone, defined as the disappearance of all clinical, radiographic, and biochemical evidence of disease for at least 4 weeks, and four achieved the status of CR after completing surgery. These results emphasize the role of surgery in increasing the CR rate. Shamash et al., in a small cohort of 13 relapsed or refractory patients, obtained a relapse-free survival rate of 46% at 40 months [45] . Rick et al. obtained a RFR of 34% at 36 months in a population of relapsed or refractory patients, but no long-term survivors were observed among the prognostically worst group of patients [46] . Recently, McNeish et al., using the HD 'carboplatin -etoposide -cyclophosphamide-paclitaxel (225 mg/m 2 )' regimen in a population of 36 GCT patients, reported a 1 year OS and a 1 year EFS rate of 88 and 64%, respectively, in 24 sensitive patients [47] . In our trial, the dose of paclitaxel was increased to 250 mg/m 2 and two cycles were administered on a day 1 to 14 regimen to improve dose-intensity. A 34.1% RR was observed after these two cycles. Thirdly, considering the efficacy and availability of thiotepa in HD regimens, we introduced this drug in the first HD-CT course of our multiple program [48] . Fourthly, considering the therapeutic potential of multiple carboplatin-based courses, the principle of tandem HD therapy was maintained, and the second and third cycles were derived from our previously described tandem ICE protocol [13, 36, 37, 49] . The rational for a sequential approach was based on the assumption that the use of multiple semi-intensive cycles as front-line therapy may be more efficient before drug resistance develops. Moreover, several phase II studies have explored the potential role of tandem HD-CT, more likely to eradicate residual cancer cells than a single application of HD-CT [36, 43, 49, 50] . If the concept of multiple cycles of HD-CT seems promising, we can expect that its application as front-line therapy would enhance the results. It is in this spirit that Hartmann et al. have reported their experience with sequential HD VIP-chemotherapy with PBSCT as first-line treatment in 28 patients with primary mediastinal GCT. With a median follow-up of 22 months, 61% achieved a CR/PRmstatus. Two-year PFS and OS rates were 54% and 64%, respectively. For the authors, these results may indicate that the use of intensive first-line treatment leads to an approximately 10% improvement in survival in patients with mediastinal GCTs [50] .
In conclusion, these results support further studies on multiple HD-CT courses in relapsed poor prognosis GCTs. Earlier intervention should allow us to improve the results and decrease the toxicity of these sequential high dose approaches, notably the toxic death rate, which remains too high [36, 44] . Better selection criteria have to be fulfilled. The role of surgery for residual tumors after HD-CT must be recalled [51] . With this in mind, the Groupe d'Etudes des Tumeurs Uro-Génitales (Genito-Urinary Tract Tumor Study Group) have started the TAXIF-II protocol, targeting non-refractory patients, and in which CPM is replaced by higher dose paclitaxel (360 mg/m 2 ), combined with higher doses of thiotepa (720 mg/m 2 ) as reported by Fields et al. [52] and in which a 12 g/m 2 dose of IFM is proposed, as in the original ICE regimen [13, 52] . The time has come to apply new and more intensive treatments in populations of patients who could clearly benefit from HD-CT.
